Антагонисты и ингибиторы лейкотриенов в терапии бронхиальной астмы

1. Abraham W.M., Stevenson J.S. A new leukotriene D4 antagonist L-660711 blocks allergen-induced late responses in allergic sheep / / FASEB J .— 1988.— Vol.2.— P.4425.

2. Adelroth E., Morris M.M., Hargreave F.E., O’Byrne P.M. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patient with asthma and normal controls / / N. Engl. J. Med.— 1986.— Vol.315.— P.480—484.

3. Ann J.P., Lee T.H. Sulphidopeptide leukotriene in asthma / / # Clin. Sci.— 1993.— Vol.84.— P.501—510.

4. Barnes N.C., Kuitert L. Influence of leukotriene antagonists on baseline pulmonary function and asthm atic responses / / Adv. Prostagland. Thrombox. Leukotr. Res.— 1994.— Vol.22.— P.217—226.

5. Barnes P.J., Lee Т.Н. Recent advances in asthma / / Postgrad. Med. J.— 1992.— Vol.68.— P.942—953.

6. Bateman E.D., Holgate S.Т., Binks S.М., Tams I.P. A multicentre study to assess the steroid — sparing potential of Accolate (zafirlucast; 20m g b d ) / / Allergy.— 1995.— Vol.50, Suppl.26.— P.320.

7. Becker A.B., Black C., Lilley M.K. et al. Antiasthmatic effects of leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs / / J. Appl. Physiol.— 1995.— Vol.78.— P.615—622.

8. Bel E.H., Tanaka W., Spector R. et al. MK-886, an effective oral leukotriene biosynthesis inhibitor on antigen-induced early and late asthm atic reactions in man / / Am. Rev. Respir. Dis.— 1990.— Vol.141.— P.A31.

9. Bel E.H ., van der Veen H., Kramps I.A. et al. Maximal airway narrow ingto inhaled leukotriene D4 in normal subjects / / Ibid.— 1987.— Vol.136.— P.979—984.

10. Bisgaard H., Groth S., Madsen F. Bronchial hyperreactivity to leukotriene D4 and histamine to exogenous asthma / / Br. Med. j . _ 1985.— Vol.290.— P.1468—1471.

11. Bochnowicz J., Underwood D.C. Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea-pig / / Prostagland. Leukotr. Essent Fatty Acids.— 1995.— Vol.52.— P.403—411.

12. Bone R.C. Asthma: new treatments will improve disease management / / Clin. Pulmon. M ed.— 1995.— Vol.2, № 5.— P.249—257.

13. Boot J.R., Bond A., Thomas K.H. et al. The pharmacology of LY 290324 in the guinea-pig: an orally active, potent and selective cysteinyl leikotriene receptor antogonist / / Eur. J. Pharmacol.— 1993.— Vol.231.— P.83—89.

14. Borgeat P., Samuelsson B. Leukotrienes: M ediators of immediate hypersensitivity reactions and infflammation / / Proc. Natl. Acad. Sci. USA.— 1979.— Vol.76.— P.3213—3217.

15. Brooks D.W., Summers J.B., Stewart A.O. et al. Novel inhibitors of leukotriene biosynthesis / / Perspectives in Medicinal Chemistry.— Weinheim, 1993.— P .119—134.

16. Busse W.W., Gaddy J.N. The role of leukotriene antagonists and inhibitors in the treatm ent airway disease / / Am. Rev. Respir. Dis.— 1991,— V ol.143.— P.103—107.

17. Brideau C., Chan C., Charleson S. et al. Pharmacology of MK-0591, a potent orally active leukotriene biosynthesis inhibitor / / Can. J. Physiol. Pharmacol.— 1992.— Vol.70.— P.799—807.

18. Busse W.W., Gaddy J.N. The role of leukotriene antagonists and inhibitors in the treatm ent of airway disease / / Am. Rev. Respir. Dis.— 1991,— V ol.143, Pt 2.— P.S103—S107.

19. Calhoun W.J., Lavins B.J., Glass M. Effect of ‘Accolate’ (zafirlucast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthm a / / Am. J. Respir. Crit. Care M ed.— 1995.— Vol.151, Pt 2.— P.A42.

20. Calverley P.M.A. Asthma / / Postgrad. Med. J.— 1996.— Vol.72,— P.12—18.

21. Carruthers N.I., Kaminski J.J. Recent developments with investigational drugs potentially useful in the treatm ent of allergic and inflammatory disorders / / Exp. Opin. Invest. Drugs.— 1995.— Vol.4.— P.1021 — 1025.

22. Carter G.W., Voung P.R., Albert D.R. et al. 5-Lipoxygenase inhibitory activity of Zeleuton / / J. Pharmacol. Exp. Ther.— * 1991.— Vol.256.— P.929—937.

23. Chanarin N., Johnston S.L. Leukotrienes as a target in asthma therapy / / Drugs.— 1994.— Vol.47.— P.12—24.

24. Christie P.E., Tagari P., Ford-Hutchinson A.W. et al. Urinary leukotriene E4 concentracions increase after aspirin challenge in aspirin-sensitive asthm atic subjects / / Am. Rev. Respir. Dis.— 1991.— Vol.143.— P.1025—1029.

25. Chung K.F. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy / / Eur. Respir. J.— 1995,— Vol.8.— P.1203—1213.

26. Dahlen B. Leukotrienes as mediators of asthma induced by aspirin and allergen 1993, 1-68 / / ISBN: 91-628-0961-X.

27. Dahlen B., Dahlen S.E. Leukotrienes as mediators of airway obstruction and inflammation in asthma / / Clin. Exp. Allergy.— 1995.— Vol.25, Suppl. 2.— P.50—54.

28. Dahlen B., Zetterstrom O., Bjorck T. et al. The leukoctriene antagonist ICI-204219 inhibits the aerly airway reaction to cum ulative bronchial challenge with allergen in atopic asthm atics / / Eur. Respir. J.— 1994.— Vol.7.— P.324—331.

29. Dahlen S.E., Bjork J., Hedqvist P. et al. Leukotrienes promotes plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response / / Proc. Natl. Acad. Sci. USA.— 1981.— Vol.78.— P.3887—3891.

30. Dahlen S.E., Dahlen B., Kumlin M., Bjoerck T., Ihre E. Clinical and experimental studies of leukotrienes as mediators of airway obstruction in humans / / Adv. Prostagland. Thrombox. Leukotr. Res.— 1994.— Vol.22.— P.155—166.

31. Dahlen S.E., Hedqvist P., Hammarstrom S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi / / Nature.— 1980.— Vol.288.— P.484—486.

32. Daines R.A., Chambers P.A., Pendrak I. et al. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships / / J. Med. Chem.— 1993.— Vol.36.— P.3321—3332.

33. Dixon R.A.F., Diehl R.E., Opas E. et al. Requirement of a 5-lipoxygenase protein for leukotriene synthesis / / Nature.— 1990.— Vol.343.— P.282—284.

34. Drazen J. The role of leukotrienes in asthm a. M ediating the inflammation in asthma / / European Academy of Allergology and Clinical Immunology. Satellite Symposium.— Rotterdam, 1993.— P.4.

35. Drazen J.M., Austen K.F. Leukotrienes and airway responses / / Am. Rev. Respir. Dis.— 1987.— Vol.136.— P.985—988.

36. Drazen J.M., Lilly C.M., Sperling R., Rubin P., Israel E. Role of cysteinil leucotrienes in spontaneus asthmatic responses / / Adv. Prostagland. Thrombox. Leukotr. Res.— 1994.— Vol.22.— P.251—262.

37. Evans T.W., Rogers D.F., Aursudkij B. et al. Regional and time-dependent effects of inflammatory on airway microvascular permeability in the guinea-pig / / Clin. Sci.— 1989.— Vol.76.— P.479—485.

38. Findlay S.R., Barden J.M., Easley C.B. et al. Effect of the oral leukotriene antagonist JCJ 204. 219 on antigen-induced bronchoconstriction in subjects with asthma / / J. Allergy Clin. Immunol.— 1992.— Vol.89.— P. 1040— 1045.

39. Floreani A., Robbins R., Melson J., Rennard S. Inhibitory effect of LTD4 receptor antagonist ‘Accolate on agonistinduced bronchoconstriction in asthmatic subjects / / Ann. Allergy. Asthma Immunol.— 1996.— Vol.76.— P.98.

40. Ford-Hutchinson A.W., Bray M.A., Doig M.E. et al. Leukotriene B: a potent chemokinetic and aggregating sustance released from polymorphonuclear leukocytes / / Nature.— 1980.— Vol.286.— P.264.

41. Foster A., Chan C.C. Peptide leukotriene involment in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig / / Arch. Allergy Appl. Immunol.— 1991.— Vol.96.— P.279—284.

42. Friedman B.S., Bel E.H., Buntinx A. et al. Oral leukotriene inhibitor (MK-886) blocks allergen- induced airway responses / / Am. Rev. Respir. Dis.— 1993.— Vol.147.— P.839—844.

43. Fujimura M., Sakamoto S., Kamio Y. et al. Effect of a leukotriene antagonist ONO-1078 on bronchial hyperresponsiveness in patients with asthma / / Respir. Med.— 1993.— Vol.87.— P. 133— 138.

44. Fuller R.W., Black P.N., Dolley C.T. Effect of the oral leukotriene D4 antagonist LY 171883 on inhaled and inradermal challenge with antigen and leukotriene D4 in atopic subjects / / J. Allergy Clin. Immunol.— 1989.— Vol.83.— P.939— 944.

45. Gaddy J.N., Buch R.K., Margoleskee D. et al. The effects of leukotriene D4 antagonist (MK 571) in mild to moderate asthma / / J. Allergy Clin. Immunol.— 1990.— Vol.85.— P .195.

46. Gaddy J.N., Margoleskee D.J., Buch R.K. et al. The effects of a potent and selective leucotriene D4 antagonist (MK 571) in moderate asthm a / / Am. Rev. Respir. Dis.— 1992.— Vol. 146.— P.358—363.

47. Gillard J., Ford-Hutchinson A.W., Chan C. et al. MK-886, njvel orally active leukotriene biosynthesis inhibitor / / Can. J. Physiol. Pharm acol.— 1989.— Vol.67.— P.456—464.

48. Glass M. Initial results with oral administration of ICI 204219 / / Ann. N. Y. Acad. Sei.— 1991.— Vol.629.— P.143—147.

49. Haahtela T. The importance of inflammation in early asthma / / Respir. M ed.— 1995.— Vol.89, № 7.— P.461—462.

50. Harris R.R., Carter G.W., Bell R. et al. Clinical activity of leukotriene inhibitors / / Int. J. Immunopharmacol.— 1995.— Vol.17,— P.147—156.

51. Hay D.W.P., Muccietelli R.M., Tucker S.S. et al. Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways / / J. Pharmacol. Exp. Ther.— 1987.— Vol.243.— P.474—481.

52. Hay D.W.P., Torphy T.J., Undem B.J. Cysteinyl leukotrienes in asthm a: old mediators up to new tricks / / Trends Pharmacol. Sei.— 1995.— Vol. 16.— P.304—309.

53. Hoover R.L., Karnovsky M.J., Austen K.F. et al. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion / / Proc. Natl. Acad. Sei. USA.— 1984.— Vol.81.— P.2191— 2193.

54. Hui K.P., Barnes N.C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist / / Lancet.— 1991.— Vol.337.— P. 1062.

55. Hui K.P., Taylor J.K., Taylor G.W. et al. Effect of 5-Lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthm atic patients / / Thorax.— 1991.— Vol.46.— P.184— 189.

56. Hutchinson J.H., Reindeau D., Brideau C. et al. Thiopyrano [ 2, 3, 4 — cd] indoles as 5-Lipoxygenase inhibitors: synthesis, biological profile / / J. Med. Chem.— 1994.— Vol.37.— P.l153—1164.

57. Ishichara Y., Uchida Y., Kitamura S. Measurement of leukotrienes in peripheral venous blood from patients with bronchial asthm a / / Clin. Res.— 1985.— Vol.33.— P.466A.

58. Israel E., Dermarkarian R., Rosenberg M. et al. The effects of 5-lipoxygenase inhibitor on asthm a induced by cold dry air / / N. Engl. J. M ed.— 1990.— Vol.323.— P.1740—1744.

59. Israel E., Drazen J., Cohn J., Rubin P. A double blind m ulticenter study of Zileuton, a potent 5-Lipoxygenase inhibitor versus placebo in the treatm ent of spontaneous asthm a in adults / / J. Allergy Clin. Immunol.— 1992.— Vol.89.— P.236—238.

60. Israel E., Rubin P., Kemo I.P. et al. The effect of inhibition of 5-lipoxigenase by zileuton in mild-to-moderate asthm a / / Ann. Intern. M ed.— 1993.— Vol.119.— P.1059—1066.

61. Jacobs R.T., Veale C.A., Wolanin D.J. Pulmonary and antiallergy agents / / Annu. Rep. Med. Chem.— 1992.— Vol.27.— P. 109—118.

62. Jones T.R., Zamboni R., Belley M. et al. Pharmacology of L-660711 (MK 571): a novel potent and selective leukotriene D4 receptor antagonist / / Can. J. Physiol. Pharmacol.— 1989.— Vol.67.— P. 17—28.

63. Joris J., Majno G., Corey E.J., Lewis R.A. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction / / Am. J. Pathol.— 1987.— Vol. 126.— P. 19—24.

64. Kaliner M.A. Allergic inflammation and asthm a / / Prog. Allergy Clin. Immunol.— 1994.— Vol.3.— P.301—304.

65. Kikawa V., Hosoi S., Inoue V. et al. Exercise-induced urinary excretion of leukotriene E4 in children with atopic asthma / / Pediatr. Res.— 1991.— Vol.29.— P.455.

66. Knapp H.R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor / / N. Engl. J. M ed.— 1990.— Vol.323.— P. 1745—1748.

67. König W., Schonjeld W., Raaulf M. et al. The neutrophil and leukotrienes — basic in health and disease / / Eucosanoids.— 1990.— Vol.3.— P .l— 22.

68. Krell R.D., Aharony D., Bucker C.K. et al. The preclinical of ICI 204219, a peptide leukotriene antagonist / / Am. Rev. Respir. Dis.— 1990,— V ol.141.— P.978—987.

69. Kumlin M., Dahlen B., Bjouck T. et al. Urinary exretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthm atics / / Am. Rev. Respir. Dis.— 1992.— Vol.146.— P.96—103.

70. Labat C., Ortiz J.L., Norel X. et al. A second cysteinyl leukotriene receptor in human lung / / J. Pharmacol. Exp. Ther.— 1992.— Vol.63.— P.800—805.

71. Laitinen L.A., Laitinen A., Haahtela T. et al. Leukotriene E4 and granulocytic infiltration into asthm atic airways / / Lancet.— 1993.— Vol.341.— P.989—990.

72. Lam S., Chan H., LeRiche J.C. et al. Realese of leukotrienes in patients with bronchial asthm a / / J. Allergy Clin. Immunol.— 1988,— Vol.81.— P.1711 — 1717.

73. Lammers J.W., Cheng J.B. Early efficacy data with a newer generation of LTD4 antagonists in anti-asthma trials / / Pulmon. Pharmacol.— 1992.— Vol.5.— P.121 — 125.

74. Lay S.R., Barden J.M ., Easley C.B. et al. Effect of the oral leukotriene antagonist JC J 204219 on antigen-induced bronchoconstriction in subjects with asthm a / / J. Allergy Clin. Im munol.— 1992.— Vol.89.— P.1040— 1045.

75. Larsen J.S. Leukotriene — receptor antagonists and 5 — lipoxygenase inhibitors in asthm a / / Ann. Pharm acother.— 1993.— Vol.27.— P.898—903.

76. Lazarus S.T., Lavins B.J., Wong H., Watts M.J., Minkwitz M.C. Effect of oral ‘Accolate’ on sulfur dioxide (S02) — induced bronchoconstriction in patients with asthm a / / Am. J. Respir. Crit. Care M ed.— 1995.— V ol.151, Pt 2.— P.A41.

77. Maclouf J., Fitzpatrick F.A., Murphy R.C. Transcellular biosynthesis of eicosanoids / / Pharmacol. Res.— 1989.— Vol.21.— P .l—7.

78. Makker H.K., Lau L.C., Thomson H.W. et al. The protective effect of inhaled leucotriene D4 receptor antagonist ICI 204219 against exercise — induced asthm a / / Am. Rev. Respir. Dis.— 1993.— V ol.147, Pt 1.— P.1413—1418.

79. Manning P.J., Rokach J., Malo J.-L. et al. Urinary leukotriene E4 levels during early and late asthm atic responses / / J. Allergy Clin. Immunol.— 1990.— Vol.86.— P .211—220.

80. Manning P.J., Watson R.M., Morgolskee D.J. et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist / / N. Engl. J. M ed.— 1990.— Vol.323.— P. 1736—1739.

81. Margolskee D., Bodtnan S., Dockhorn R. et al. The therapeutic effects of MK-571, a potent and selective leukotriene D4, receptor antagonist in patients with chronic asthm a / / J. Allergy Clin. Immunol.— 1991.— Vol.87.— P.309.

82. Marom Z.V.L., Shelhamer J.H., Bach M.K. et al. Slow-reacting substance, leukotrienes C4 and D4, icrease the realease of mucus from human airways in vitro / / Am. Rev. Respir. Dis.— 1982.— Vol.126.— P.449—451.

83. Miller D.K., Gillard J.W., Vickers P.J. et al. Indentification and isolation of a membrane protein necessary for leukotriene production / / N ature.— 1990.— Vol.343.— P.278—281.

84. Morris H.R., Taylor G.W., Piper P.J., Tippins J.R. Structure of slow reacting substance of anaphylaxis from guinea-pig lung / / Ibid.— 1980.— Vol.285.— P.104—106.

85. Murphy R.C., Hammarstrom S., Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells / / Proc. Natl. Acad. Sei. USA.— 1979.— Vol.76.— P.4275—4279.

86. Nakai H., Konno M., Kosuge S. et al. New potent antagonist of leukotrienes C4 and D4 1. Synthesis and structure-activity relationships / / J. Med. Chem.— 1988.— Vol.34.— P.84.

87. Nakagawa N., Obata T. Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthm a / / Eur. J. Pharmacol.— 1993.— Vol.235.— P .211—219.

88. Obata T., Okada Y., Motoishi M. et al. In vitro antagonism ONO-1078, a newly developed antiasthm a agent, against peptide leukotrienes in isolated guinea pig tissues / / Jap. J. Pharm acol.— 1992.— Vol.60.— P.227—230.

89. O’Hickey S.P., Hawksworth J., Fong C.V. et al. Leukotrienes C4D4-E4 enhance histamine responsiveness in asthm atic airways / / Am. Rev. Respir. Dis.— 1991.— V ol.144.— P .1053—1057.

90. Ohmi Naoko, Tani C., Yamada K., Fukui M. Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178 / / Iflammation.— 1994.— V ol.18.— P.129—140.

91. Picado C., Ramis I., Rosello J. et al. Release of peptide leukotriene in to nasal secretions after local instillation of aspirin in aspirin sensitive asthm atic patients / / Am. Rev. Respir. Dis.— 1991.— Vol.145.— P.65—69.

92. Piper P.J. Formation and actions of leukotrienes / / Pharmacol. Rev.— 1984.— Vol.64.— P.744—761.

93. Piper P.J. Leukotriene in airways and blood vessels / / Arzneim.- Forsch.— 1989.— Bd 39.— S. 1005—1009.

94. Piper P.J. Leukotrienes: potent mediators of airway constriction / / Int. Arch. Allergy Appl. Immunol.— 1985.— Vol.76, Suppl. 1.— P.43—48.

95. Rasmussen J.B., Morgolskee D.J., Eriksson L.O. et al. Leukotriene (LT) D4 is involved in antigen— induced asthma: a study with the LTD4 receptor antagonist MR— 571 / / Ann. N. Y. Acad. Sei.— 1991.— Vol.629.— P.436.

96. Roquet A., Dahlen B., Ihre E. et al. Cysteinyl-leukotriens and histamine account for predominant components of early and late phase airway obstruction evoked by allergene-challenge of asthmatics / / Am. J. Respir. Crit. Care Med.— 1996.— Vol. 154, № 4.— Pt 2.— P.A214.

97. Rouzer C.A., Ford-IJutchinson A.W., Morten H.E. MK-886, a potent and specific leukotriene biosynthesis inhibitor, blocks and reverses the membrane association of 5-lipoxygenase in ionophore challenged leukocytes / / J. Biol. Chem.— 1990.— Vol.265.— P.1436—1442.

98. Rouzer C.A., Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187 / / Ibid.— 1988.— Vol.263.— P.10980—10988.

99. Sakakibara H., Hirose K., Okawara S. Peptidoleukotriene receptor antagonists / / Nippon Rinsho.— 1996.— Vol.54.— P.3049—3055.

100. Salari H., Borgeat P., Fournier M. et al. Studies of the release of leukotrienes and histamine by human lung parenchymal and bronchial frafments upon immunologic and nonimmunologic stim ulation / / J. Exp. M ed.— 1985.— Vol.162.— P.1904—1915.

101. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reaction and inflammation / / Science.— 1983.— Vol.220.— P.568.

102. Satoh Y., Stanton J.L., Hutchinson A.J. et al. Substituted Chromenes as potent, orally active 5-lipoxigenase inhibitors / / J. Med. Chem.— 1993.— Vol.36.— P.3580—3594.

103. Schroer K. Pharmacology of allergic inflammation: new approaches to drug treatm ent by selective modulation of the formation and action of aicosanoids / / Allergologie.— 1992.— Vol. 15.— P.330—335.

104. Shaw A., Krell R.D. Peptide leukotriens: current status of research / / J. Med. Chem.— 1991.— Vol.34, № 4.— P.1235—1242.

105. Smith M.J.H., Ford-Hutchinson A.W., Bray M.A. Leukotriene B: a potencial mediator of inflammation / / J. Pharm. Pharmacol.— 1980.— Vol.32.— P.517—518.

106. Smith L.J., Geller S., Edright L. et al. Inhibition of leukotriene (LT) D4-induced bronchoconstriction in asthm atic subjects by the oral LTD4 receptor antagonist ICI 204219 / / Am. Rev. Respir. Dis.— 1990.— Vol.141.— P.A33.

107. Tagari P., Becker A.B., Brideau C. et al. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591 / / J. Pharmacol. Exp. Their.— 1993.— Vol.265.— P.416—425.

108. Tagari P., Rasmussen J.B., Delore D. et al. Comparison of urinary leukotriene E4 and 16-carboxytetranordihydroleukotriene E4 excretion in allergic asthm atics after inhaled antigen / / Eicosanoids.— 1990.— Vol.3.— P.75—80.

109. Taniguchi Y., Tamura G., Honma M. et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthm atic subjects / / J. Allergy Clin. Immunol.— 1993.— Vol.92.— P.507—512.

110. Taylor I.K. Cysteinyl leukotriene in asthma: current state of therapeutic evalution / / Thorax.— 1995.— Vol.50.— P. 1005—1010.

111. Taylor G.W., Black P., Turner N. et al. Urinary leukotriene E4 after antigen challenge in acute asthma and allergic rhinitis / / Lancet.— 1989.— V ol.l.— P.584—588.

112. Taylor I.K., O’Shaughnessy K.M., Choudry N.B. et al. A comparative stady in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity and increase in urinary leukotriene E4 excretion / / J. Allergy Clin. Immunol.— 1992.— Vol.89.— P.575—583.

113. Taylor W.A. Eicosanoids in asthma: the therapeutic options / / Perspectives in Medicinal Chemistry / Ed. B. Testa, E. Kuburz et al.— Weinheim, 1993.— P.445—458.

114. Virchow J.C., Kroegel C., Luttman W. et al. Leukotriene-receptor-antagonists, 5-lipoxygenase-activating-protein inhibitors — a new form of therapy in bronchial asthma / / Allergologie.— 1996.— Vol.19, № 1.— P.3—14.

115. Wardlaw A.J., Hay H., Cromwell O. et al. Leukotrienes, LTC4 and LTD4 in bronchoalveolar lavage in bronchial asthma and respiratory diseases / / J. Allergy Clin. Immunol.— 1989.— Vol.84.— P. 19—26.

116. WEI Er-Qing, XIN Xiao-Hua et al. Effects of ONO-1078, a lekotriene antagonist, on cardiovascular responses induced by vagal stimulation, capsaicin, and substance P in guinea pigs / / Acta Pharmacol. Sin.— 1995.— Vol.16.— P.485—488.

117. Weiss J.W., Drazen J.M., Coles H. Bronchoconstrictor effects of leukotriene C in humans / / Science.— 1982.— Vol.216.— P.196—198.

118. Whealan C.J. Prospects for the development of new drags for the therapy of respiratory diseases / / Drugs Today.— 1996.— Vol.32.— P.295—311.

119. Woodward D.F., Weichman B.M., Gill C.A., Wasserman M.A. The effect of synthetic leukotrienes on tracheal microvascular permeability / / Prostaglandins.— 1983.— Vol.25.— P.131—142.

120. Zakrzewski J.T., Barnes H.C., Piper P.J. Quantitation of leukotrienes in asthmatic sputum / / Br. J. Pharmacol.— 1985.— Vol.19.— P.574.